# GLORY: Glofit-GemOx With Liso-Cel For Lymphoma

> **NCT07711483** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Lymphoma
- B-cell Lymphomas
- Relapsed/Refractory Large B-cell Lymphoma
- Large B-cell Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Glofitamab
- **DRUG:** Gemcitabine & oxaliplatin
- **PROCEDURE:** Leukapheresis
- **DRUG:** Lymphodepleting chemotherapy
- **DRUG:** LISOCABTAGENE MARALEUCEL

## Key facts

- **NCT ID:** NCT07711483
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-14
- **Primary completion:** 2028-10-01
- **Final completion:** 2030-10-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711483, "GLORY: Glofit-GemOx With Liso-Cel For Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*